Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2018

Open Access 01-12-2018 | Study protocol

The comparative effectiveness of decision aids in diverse populations with early stage prostate cancer: a study protocol for a cluster-randomized controlled trial in the NCI Community Oncology Research Program (NCORP), Alliance A191402CD

Authors: Joel E. Pacyna, Simon Kim, Kathleen Yost, Hillary Sedlacek, Daniel Petereit, Judith Kaur, Bruce Rapkin, Robert Grubb, Electra Paskett, George J. Chang, Jeff Sloan, Ethan Basch, Brittny Major, Paul Novotny, John Taylor, Jan Buckner, J. Kellogg Parsons, Michael Morris, Jon C. Tilburt

Published in: BMC Cancer | Issue 1/2018

Login to get access

Abstract

Background

Treatments for localized prostate cancer present challenging tradeoffs in the face of uncertain treatment benefits. These options are best weighed in a process of shared decision-making with the patient’s healthcare team. Minority men experience disparities in prostate cancer outcomes, possibly due in part to a lack of optimal communication during treatment selection. Decision aids facilitate shared decision-making, improve knowledge of treatment options, may increase satisfaction with treatment choice, and likely facilitate long-term quality of life.

Methods/design

This study will compare the effect of two evidence-based decision aids on patient knowledge and on quality of life measured one year after treatment, oversampling minority men. One decision aid will be administered prior to specialist consultation, preparing patients for a treatment discussion. The other decision aid will be administered within the consultation to facilitate transparent, preference-sensitive, and evidence-informed deliberations. The study will utilize a four-arm, block-randomized design to test whether each decision aid alone (Arms 1 and 2) or in combination (Arm 3) can improve patient knowledge and quality of life compared to usual care (Arm 4). The study, funded by the National Cancer Institute’s Community Oncology Research Program (NCORP), will be deployed within select institutions that have demonstrated capacity to recruit minority populations into urologic oncology trials.

Discussion

Upon completion of the trial, we will have 1) tested the effectiveness of two evidence-based decision aids in enhancing patients’ knowledge of options for prostate cancer therapy and 2) estimated whether decision aids may improve patient quality of life one year after initial treatment choice.

Trial registration

Clinicaltrials.gov: NCT03103321. The trial registration date (on ClinicalTrials.gov) was April 6, 2017.
Literature
1.
Bach PB, Schrag D, Brawley OW, Galaznik A, Yakren S, Begg CB. Survival of blacks and whites after a cancer diagnosis. JAMA. 2002;287(16):2106–13.CrossRefPubMed
2.
Cohen JH, Schoenbach VJ, Kaufman JS, et al. Racial differences in clinical progression among Medicare recipients after treatment for localized prostate cancer (United States). Cancer causes & control : CCC. 2006;17(6):803–11.CrossRefPubMed
3.
Du XL, Fang S, Coker AL, et al. Racial disparity and socioeconomic status in association with survival in older men with local/regional stage prostate carcinoma: findings from a large community-based cohort. Cancer. 2006;106(6):1276–85.CrossRefPubMed
4.
Godley PA, Schenck AP, Amamoo MA, et al. Racial differences in mortality among Medicare recipients after treatment for localized prostate cancer. J Natl Cancer Inst. 2003;95(22):1702–10.CrossRefPubMed
5.
Espey DK, Wu XC, Swan J, et al. Annual report to the nation on the status of cancer, 1975-2004, featuring cancer in American Indians and Alaska natives. Cancer. 2007;110(10):2119–52.CrossRefPubMed
6.
Henderson JA, Espey DK, Jim MA, German RR, Shaw KM, Hoffman RM. Prostate cancer incidence among American Indian and Alaska native men, US, 1999-2004. Cancer. 2008;113(5 Suppl):1203–12.CrossRefPubMed
7.
Hoffman RM, Harlan LC, Klabunde CN, et al. Racial differences in initial treatment for clinically localized prostate cancer. Results from the prostate cancer outcomes study. J Gen Intern Med. 2003;18(10):845–53.CrossRefPubMedPubMedCentral
8.
Klabunde CN, Potosky AL, Harlan LC, Kramer BS. Trends and black/white differences in treatment for nonmetastatic prostate cancer. Med Care. 1998;36(9):1337–48.CrossRefPubMed
9.
Pisu M, Oliver JS, Kim YI, Elder K, Martin M, Richardson LC. Treatment for older prostate cancer patients: disparities in a southern state. Med Care. 2010;48(10):915–22.CrossRefPubMed
10.
Pollack CE, Bekelman JE, Epstein AJ, Liao K, Wong YN, Armstrong K. Racial disparities in changing to a high-volume urologist among men with localized prostate cancer. Med Care. 2011;49(11):999–1006.PubMedPubMedCentral
11.
Trinh QD, Sammon J, Sun M, et al. Perioperative outcomes of robot-assisted radical prostatectomy compared with open radical prostatectomy: results from the nationwide inpatient sample. Eur Urol. 2012;61(4):679–85.CrossRefPubMed
12.
Underwood W, 3rd, Jackson J, Wei JT, et al. Racial treatment trends in localized/regional prostate carcinoma: 1992-1999. Cancer 2005;103(3):538–545.
13.
Wong YN, Mitra N, Hudes G, et al. Survival associated with treatment vs observation of localized prostate cancer in elderly men. JAMA. 2006;296(22):2683–93.CrossRefPubMed
14.
Hu JC, Kwan L, Krupski TL, et al. Determinants of treatment regret in low-income, uninsured men with prostate cancer. Urology. 2008;72(6):1274–9.CrossRefPubMed
15.
Hu JC, Kwan L, Saigal CS, Litwin MS. Regret in men treated for localized prostate cancer. J Urol. 2003;169(6):2279–83.CrossRefPubMed
16.
Hosain GM, Sanderson M, Du XL, Chan W, Strom SS. Racial/ethnic differences in treatment discussed, preferred, and received for prostate cancer in a tri-ethnic population. Am J Mens Health. 2012;6(3):249–57.CrossRefPubMedPubMedCentral
17.
Kim SP, Boorjian SA, Shah ND, et al. Disparities in access to hospitals with robotic surgery for patients with prostate cancer undergoing radical prostatectomy. J Urol. 2013;189(2):514–20.CrossRefPubMed
18.
Pitman M, Korets R, Kates M, Hruby GW, McKiernan JM. Socioeconomic and clinical factors influence the interval between positive prostate biopsy and radical prostatectomy. Urology. 2012;80(5):1027–32.CrossRefPubMed
19.
Siegel R, Naishadham D, Jemal A. Cancer statistics for Hispanics/Latinos, 2012. CA Cancer J Clin. 2012;62(5):283–98.CrossRefPubMed
20.
Siegel RL, Fedewa SA, Miller KD, et al. Cancer statistics for Hispanics/Latinos, 2015. CA Cancer J Clin. 2015;65(6):457–80.CrossRefPubMed
21.
White A, Coker AL, Du XL, Eggleston KS, Williams M. Racial/ethnic disparities in survival among men diagnosed with prostate cancer in Texas. Cancer. 2011;117(5):1080–8.CrossRefPubMed
22.
Winkfield KM, Chen MH, Dosoretz DE, et al. Race and survival following brachytherapy-based treatment for men with localized or locally advanced adenocarcinoma of the prostate. Int J Radiat Oncol Biol Phys. 2011;81(4):e345–50.CrossRefPubMed
23.
Allen JD, Kennedy M, Wilson-Glover A, Gilligan TD. African-American men's perceptions about prostate cancer: implications for designing educational interventions. Social science & medicine (1982). 2007;64(11):2189–2200.
24.
Stacey D, Legare F, Lewis K, et al. Decision aids for people facing health treatment or screening decisions. The Cochrane database of systematic reviews. 2017;4:Cd001431.
25.
Trikalinos TA, Wieland LS, Adam GP, Zgodic A, Ntzani EE. AHRQ Comparative Effectiveness Reviews. Decision Aids for Cancer Screening and Treatment. Rockville (MD): Agency for Healthcare Research and Quality (US); 2014.
26.
Brown AW, Li P, Bohan Brown MM, et al. Best (but oft-forgotten) practices: designing, analyzing, and reporting cluster randomized controlled trials. Am J Clin Nutr. 2015;102(2):241–8.CrossRefPubMedPubMedCentral
27.
28.
29.
D'Amico AV, Whittington R, Malkowicz S, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA. 1998;280(11):969–74.CrossRefPubMed
30.
Wei JT, Dunn RL, Litwin MS, Sandler HM, Sanda MG. Development and validation of the expanded prostate cancer index composite (EPIC) for comprehensive assessment of health-related quality of life in men with prostate cancer. Urology. 2000;56(6):899–905.CrossRefPubMed
31.
Sepucha KR, Borkhoff CM, Lally J, et al. Establishing the effectiveness of patient decision aids: key constructs and measurement instruments. BMC medical informatics and decision making. 2013;13 Suppl 2:S12.
32.
Collins D. Pretesting survey instruments: an overview of cognitive methods. Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation. 2003;12(3):229–38.CrossRef
33.
O'Connor AM. Validation of a decisional conflict scale. Medical decision making : an international journal of the Society for Medical Decision Making. 1995;15(1):25–30.CrossRef
34.
35.
Brehaut JC, O'Connor AM, Wood TJ, et al. Validation of a decision regret scale. Medical decision making : an international journal of the Society for Medical Decision Making. 2003;23(4):281–92.CrossRef
36.
Stacey D, Legare F, Lewis KB. Patient decision aids to engage adults in treatment or screening decisions. JAMA. 2017;318(7):657–8.CrossRefPubMed
37.
Donner A, Klar N. Design and analysis of cluster randomization trials in health research. London: Arnold; 2000.
38.
Chu R, Thabane L, Ma J, Holbrook A, Pullenayegum E, Devereaux PJ. Comparing methods to estimate treatment effects on a continuous outcome in multicentre randomized controlled trials: a simulation study. BMC Med Res Methodol. 2011;11:21.CrossRefPubMedPubMedCentral
39.
Keirns CC, Goold SD. Patient-centered care and preference-sensitive decision making. JAMA. 2009;302(16):1805–6.CrossRefPubMed
40.
O'Connor AM, Llewellyn-Thomas HA, Flood AB. Modifying unwarranted variations in health care: shared decision making using patient decision aids. Health affairs (Project Hope). 2004;Suppl Variation:Var63–72.
41.
Wennberg JE, Fisher ES, Skinner JS. Geography and the debate over Medicare reform. Health affairs (Project Hope). 2002;Suppl Web Exclusives:W96–114.
42.
Berwick DM. Quality chasm factors. Health affairs (Project Hope). 2002;21(5):301–2. author reply 303CrossRef
43.
Berwick DM. A user's manual for the IOM's 'Quality Chasm' report. Health affairs (Project Hope). 2002;21(3):80–90.CrossRef
44.
Mohler J, Bahnson RR, Boston B, et al. NCCN clinical practice guidelines in oncology: prostate cancer. Journal of the National Comprehensive Cancer Network : JNCCN. 2010;8(2):162–200.CrossRefPubMed
45.
Thompson I, Thrasher JB, Aus G, et al. Guideline for the management of clinically localized prostate cancer: 2007 update. J Urol. 2007;177(6):2106–31.CrossRefPubMed
Metadata
Title
The comparative effectiveness of decision aids in diverse populations with early stage prostate cancer: a study protocol for a cluster-randomized controlled trial in the NCI Community Oncology Research Program (NCORP), Alliance A191402CD
Authors
Joel E. Pacyna
Simon Kim
Kathleen Yost
Hillary Sedlacek
Daniel Petereit
Judith Kaur
Bruce Rapkin
Robert Grubb
Electra Paskett
George J. Chang
Jeff Sloan
Ethan Basch
Brittny Major
Paul Novotny
John Taylor
Jan Buckner
J. Kellogg Parsons
Michael Morris
Jon C. Tilburt
Publication date
01-12-2018
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2018
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-018-4672-3

Other articles of this Issue 1/2018

BMC Cancer 1/2018 Go to the issue

Research article

Characterization of primary normal and malignant breast cancer cell and their response to chemotherapy and immunostimulatory agents

Research article

Physical activity patterns and the risk of colorectal cancer in the Norwegian Women and Cancer study: a population-based prospective study

Research article

Spatially varying effects of predictors for the survival prediction of nonmetastatic colorectal Cancer

Research article

DNA methylation signatures of breast cancer in peripheral T-cells

Research article

Co-culture of dendritic cells and cytokine-induced killer cells effectively suppresses liver cancer stem cell growth by inhibiting pathways in the immune system

Study protocol

CRITICS-II: a multicentre randomised phase II trial of neo-adjuvant chemotherapy followed by surgery versus neo-adjuvant chemotherapy and subsequent chemoradiotherapy followed by surgery versus neo-adjuvant chemoradiotherapy followed by surgery in resectable gastric cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits